This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Samuele Cazzamalli, Ph.D.
Head of Small Molecule Therapeutics at Philochem Ag

Profile

Samuele Cazzamalli studied Medicinal Chemistry at the University of Milan. During his doctoral studies at ETH Zürich in the group of Prof. Dario Neri (2015-2018), Samuele has generated novel Antibody-Drug Conjugate, Small Molecule-Drug Conjugate and Small Molecule-Radio Conjugate products for applications in oncology.

Samuele heads now the Small Molecule Therapeutics R&D unit at Philochem AG (Switzerland), focusing on the development of products based on small organic ligands for tumor-targeting applications.

Agenda Sessions

  • Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein in solid lesions

    15:00